Table 2. Adverse cardiovascular events by immune checkpoint inhibitor.
Occurrence of ACE and individual components of ACE, by single ICI versus dual ICI therapy, as well as by specific ICI agents.
| ACE | ARRHYTHMIA | ASCVD | HEART FAILURE | VALVULAR DISEASE | PERICARDIAL DISEASE | MYOCARDITIS | |
|---|---|---|---|---|---|---|---|
| Single ICI therapy | 43.2% (788/1823) | 20.2% (368/1823) | 27.5% (502/1823) | 11.1% (202/1823) | 6.4% (117/1823) | 1.9% (34/1823) | 0.5% (10/1823) |
| Dual ICI therapy | 50.9% (174/342) | 22.2% (76/342) | 31% (106/342) | 13.2% (45/342) | 7% (24/342) | 1.8% (6/342) | 2% (7/342) |
| P-value | 0.011 | 0.382 | 0.191 | 0.267 | 0.635 | 1.000 | 0.011 |
|
ICI Agent | |||||||
| Nivolumab | 41.6% (279/670) | 19.1% (128/670) | 28.4% (190/670) | 10.6% (71/670) | 6.1% (41/670) | 1.2% (8/670) | 0.3% (2/670) |
| Pembrolizumab | 43.1% (333/773) | 19.9% (154/773) | 26.8% (207/773) | 11.4% (88/773) | 7.1% (55/773) | 1.9% (15/773) | 0.9% (7/773) |
| Ipilimumab | 52.2% (96/184) | 20.1% (37/184) | 37% (68/184) | 9.8% (18/184) | 9.2% (17/184) | 1.1% (2/184) | 0.5% (1/184) |
| Atezolizumab | 44.3% (94/212) | 22.6% (48/212) | 24.5% (52/212) | 11.3% (24/212) | 5.2% (11/212) | 1.9% (4/212) | 0.5% (1/212) |
| Durvalumab | 37.9% (36/95) | 18.9% (18/95) | 25.3% (24/95) | 8.4% (8/95) | 4.2% (4/95) | 2.1% (2/95) | 0.0% (0/97) |
| Avelumab | 45.5% (5/11) | 9.1% (1/11) | 18.2% (2/11) | 0% (0/11) | 9.1% (1/11) | 18.2% (2/11) | 0.0% (0/12) |
| Cemiplimab | 40% (2/5) | 20.0% (1/5) | 0.0% (0/5) | 40.0% (2/5) | 0.0% (0/5) | 20.0% (1/5) | 0.0% (0/5) |
ASCVD: Atherosclerotic cardiovascular disease, including acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD).